Athersys, Inc. ATHX was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.01 –$2.55 in the past one-month time frame, witnessed a sharp increase yesterday.
The upmove came after the company announced that it has entered into a manufacturing services agreement with Nikon CeLL to commercially produce its stem cell therapy, MultiStem, for ischemic stroke.
The company has seen no estimate revisions over the past few weeks and the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Athersys currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Athersys, Inc. Price
Athersys, Inc. Price | Athersys, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Axovant Sciences Ltd. AXON, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ATHX going up? Or down? Predict to see what others think: Up or Down
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Athersys, Inc. (ATHX) : Free Stock Analysis Report
Axovant Sciences Ltd. (AXON) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research